Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To provide idelalisib in an open-label format prior to the expected time of regulatory approval to subjects with relapsed CLL who have limited treatment options.
Critère d'inclusion
- Chronic lymphocytic leukemia